… with non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative
example of the successes in targeting oncogene addiction in cancer and the role of tumor-…

… Lung cancer is the leading cause of cancer-related mortality globally, … lung cancer (NSCLC)
is the most common type of lung cancer, accounting for approximately 80–90% of all lung …

… New discoveries of potent kinase inhibitors and … kinase inhibitors against NSCLC, along
with medicinal chemistry aspects and related developments in next-generation kinase inhibitors …

… checkpoint blockade in patients with lung cancer, but the impact of … lung cancers, we found
an inverse relationship between TMB and clinical benefit of EGFR-tyrosine kinase inhibitors (…

… receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) can function as
oncogenic driver and target for precision medicine intervention in lung cancer cells [1]. Once …

… We sought to determine the relevant target of Aurora kinase inhibitors in driving drug
synergy. We found approximately twofold messenger RNA upregulation but no increase in total …

… in RET fusion-positive lung cancer treated with RET tyrosine kinase inhibitors (TKIs). …
Importantly, lung cancers harboring RET fusions are sensitive to tyrosine kinase inhibitors (TKIs) …

… inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor
receptor-tyrosine kinase inhibitors or BRAF inhibitors … other drugs with MEK inhibitors to …

… The management of metastatic non-small cell lung cancer (NSCLC) with a limited number …
standard of care for metastatic EGFRm NSCLC is tyrosine kinase inhibitor (TKI) therapy (4,5). …

… kinase inhibitors and immunotherapy for lung cancer are the … including tyrosine kinase
inhibitors, checkpoint inhibitors, and … for non-small cell lung cancer attempting to provide insights …